Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels

Internal Medicine

Volumn 46, Issue 8, 2007, Pages 447-452

  Iwata, Yasunori ^a   Wada, Takashi ^a,b   Yokoyama, Hitoshi ^c   Toyama, Tadashi ^a   Kitajima, Shinji ^a   Okumura, Toshiya ^a   Hara, Akinori ^a   Yamahana, Junya ^a   Nakaya, Izaya ^a   Kobayashi, Motoo ^a   Kitagawa, Kiyoki ^a   Kokubo, Satoshi ^a   Yoshimoto, Keiichi ^a   Shimizu, Kazuaki ^a   Sakai, Norihiko ^a   Furuchi, Kengo ^a   Koshino, Yoshitaka ^d   Takeda, Shinichi ^d   Takasawa, Kazuya ^d   Ohta, Satoshi ^d   Takaeda, Masayoshi ^d   Takaeda, Chikako ^d   Kaneko, Shuichi ^a   more..

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d The Kanazawa Study Group for Renal Diseases and Hypertension   (Japan)

Author keywords

Diabetes mellitus; Hemodialysis; Hypoparathyroidism; Low bone turnover; Sevelamer hydrochloride

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CALCIUM CARBONATE; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; SEVELAMER;

ADULT; ADYNAMIC BONE DISEASE; AGED; ARTICLE; BONE REMODELING; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPOPARATHYROIDISM; JAPANESE; MALE; MULTICENTER STUDY; OSTEODYSTROPHY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BONE REMODELING; CALCIUM; FEMALE; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; POLYAMINES; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 34247393212     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.6338     Document Type: Article

References (18)

1. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 17: 2094-2105, 2002.
2. Anca GM, Mordecai MP. Parathyroid hormone-independent osteoclastic resorptive bone disease: a new variant of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 17: 620-624, 2002.
3. Gerakis A, Hadjidakis D, Kokkinakis E, et al. Correlation of bone mineral density with the histological findings of renal osteodystrophy on hemodialysis. J Nnephrol 13: 473-443, 2000.
4. Akizawa T, Kinugasa E, Akiba T, et al. Incidence and clinical characteristics of hypoparathyroidism in dialysis patients. Kidney Int Suppl 62: S72-S74, 1997.
5. Inaba M, Nagasue Y, Okuno S, et al. Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis 39: 1261-1269, 2002.
6. Inaba M, Okuno S, Nagasue K, et al. Impaired secretion of parathyroid hormone is coherent to diabetic hemodialyzed patients. Am J Kidney Dis 38 (Suppl 1): S139-142, 2001.
7. Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29: 66-71, 1997.
8. Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33: 694-701, 1999.
9. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 14: 2907-2914, 1999.
10. Sadek T, Mazouz H, Bahloul H, et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant 18: 582-588, 2003.
11. Coen G. Adynamic bone disease: An update and overview. J Nnephrol 18: 117-122, 2005.
12. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16: 1115-1125, 2005.
13. Raggi P, James G, Burke SK, et al. Decrease in thoracic vertebral bone attenuatuion with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 20: 764-772, 2005.
14. Sugimoto T, Ritter C, Morrissey J, et al. Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int 37: 1522-1527, 1990.
15. Holgado R, Haire H, Ross D, et al. Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res 15: 927-935, 2000.
16. Ueda M, Inaba M, Okuno S, et al. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low. PTH Life Sci 77: 1130-1139, 2005.
17. Ueda M, Inaba M, Okuno S, et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 40: 802-809, 2002.
18. Botolin S, Faugere MC, Malluche H, Orth M, Meyer R, McCabe LR, et al. Increased bone adiposity and peroxisomal-activated receptor-gamma2 expression in type IO diabetic mice. Endocrinology 146: 3622-3631, 2005.